CEO of U.S. Bio Company Cashes Out Millions in Shares, CFO Joins

United Therapeutics Corp. (Nasdaq: UTHR) disclosed in a recent filing that its Chairwoman and CEO Martine A. Rothblatt and CFO James Edgemond exercised stock options between May 22 and 27 and sold the resulting shares the same days, converting millions of dollars of equity into cash. On May 22 and 27, Rothblatt exercised options on 19,000 shares at $146.03 each, then sold those shares—along with other holdings—in tranches at roughly $567–$580 per share. She realized about $5.4 million and $6.2 million in the two transactions, for a combined total of approximately $11 million (about ₩15 billion). Her direct holdings fell by roughly 1,400 shares to about 40,513, but she still retains around $23 million (₩30 billion) in market-value equity.

Edgemond exercised options on 10,000 shares at $117.76 per share on May 26 and sold them in tranches at about $560–$578 each, netting roughly $5.7 million (₩8 billion). He continues to hold 18,876 shares, valued at approximately $10.9 million (₩15 billion). All transactions were executed under prearranged Rule 10b5-1 trading plans. In Rothblatt’s case, the plan allows her to stagger the exercise and sale of a larger block of options—about 1.734 million shares expiring in March 2027—through at least December 31, 2026.

A more recent filing shows that on June 16 Rothblatt sold an additional 9,500 shares under the same 10b5-1 plan, generating about $5.22 million (₩7 billion) in proceeds. United Therapeutics’ CFO and general counsel also reported insider sales of roughly $5.5 million and $4.5 million, respectively, during June.

Separately, the company announced in March a share repurchase program of up to $2 billion (₩2.7 trillion) and reported that the TETON-1 Phase III trial of its inhaled treatment Tyvaso for idiopathic pulmonary fibrosis achieved its primary endpoint.

United Therapeutics is a Nasdaq-listed biotech specializing in rare, serious pulmonary diseases, including pulmonary arterial hypertension and idiopathic pulmonary fibrosis, with marketed products Tyvaso and Remodulin. Through its affiliate Lung Biotechnology, the company is developing artificial organs and regenerative-medicine technologies to address transplant shortages. Founder and CEO Martine A. Rothblatt is a serial entrepreneur who previously launched satellite radio company Sirius and established United Therapeutics to develop a therapy for her child’s rare disease.